Rossin Erbe

Multimodal immune profile score (IPS) signature as a predictive response biomarker to immune checkpoint inhibitors in tumor mutational burden-high (TMB-H) advanced pancancer cohorts.

Michelle Ting-Lin, Yan Liu, Matthew E. Campbell, Rossin Erbe et autres

e14590 Background: Immune checkpoint inhibitors (ICI) have altered the oncology treatment landscape with improved outcomes. Despite approved predictive biomarkers for ICI such as TMB, refining selection can identify more patients (pts) who may benefit, as most TMB-H pts still fail to achieve …

us (code pays fourni par la source)

Multiomic machine learning integration of DNA and RNA features to predict immunotherapy benefit in MSS-CRC and other rare cancers.

Michelle Ting-Lin, Yan Liu, Rossin Erbe, Alia Zander et autres

2531 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the oncology landscape, yet remain constrained by imprecise predictive biomarkers (i.e., PD-L1, TMB, MSI), which fail to capture the complexity of the tumor microenvironment. The Immune Profile Score (IPS), an AI/machine learning (ML) driven …

us (code pays fourni par la source)

Abstract 6187: Elevating bulk sequencing with high-resolution spatial transcriptomics: A paired-data analysis of clinically-relevant spatial niches in CRC and NSCLC

Yajas Shah, Tianyou Luo, Christine M. Hoeman, Luca Lonini et autres

Abstract Background: Bulk RNA-next generation sequencing (RNA-NGS) is a standard tool for the molecular characterization of solid tumors and is used in clinical practice to guide therapy selection. However, the spatial organization of the tumor microenvironment (unobservable in bulk RNA-NGS) plays an …

us (code pays fourni par la source)

134 A multi-omic immune profile score (IPS) stratifies real-world outcomes of microsatellite stable (MSS) advanced colorectal cancer patients treated with immune checkpoint inhibitors

Yan Liu, Rossin Erbe, Ailin Jin, Alia D Zander et autres

Background Immune checkpoint inhibitors (ICI) are approved in advanced colorectal cancer (CRC) patients with the microsatellite instability-High (MSI-H) biomarker. MSI-H CRC patients represent a minority of advanced CRC disease. Though the majority of CRC patients are MSS, they lack a predictive biomarker …

us (code pays fourni par la source)

157 A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors

Michelle Ting-Lin, Alia D Zander, Rossin Erbe, Yan Liu et autres

Background Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape, yet effective treatments for rare cancers remain a clinical unmet need. The scarcity and heterogeneity of rare cancers makes widespread progress challenging; a generalizable biomarker to predict response and improve patient …

us (code pays fourni par la source)

Epigenetic profiling reveals key super-enhancer networks driving oncogenesis in HPV-positive HNSCC

Fernando Tadeu Zamunér, Spencer S. Chan, Michael D. Kessler, Ilya E. Vorontsov et autres

Human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) is a growing subset of cancer cases distinct from HPV-negative by fewer genetic mutations and prevalent epigenetic dysregulation. We mapped H3K27ac-marked super-enhancers (SEs) via ChIP-seq in HPV+ patient-derived xenografts (PDXs) and normal …

us, ru (code pays fourni par la source)

Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors

Alia D Zander, Rossin Erbe, Yan Liu, Ailin Jin et autres

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. METHODS: A de-identified pan-cancer cohort from the …

us (code pays fourni par la source)

Abstract 3300: A longitudinal, circulating tumor molecular response biomarker as a predictor of clinical outcomes in a real-world cohort of patients with advanced solid tumors treated with tyrosine kinase inhibitors

John L. Guittar, Akash Mitra, Rossin Erbe, Shannon Mulmat et autres

Abstract Studies have shown that early changes in quantitative measures of circulating tumor DNA (ctDNA) in response to immunotherapy can predict clinical outcomes and may be useful for identifying molecular responders (MRs) and molecular non-responders (nMRs) who may benefit from a change …

us (code pays fourni par la source)

Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitors

Alia D Zander, Rossin Erbe, Yan Liu, Ailin Jin et autres

Abstract Background Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. Methods A de-identified pan-cancer cohort from …

us (code pays fourni par la source)

188 Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors

Alia D Zander, Rossin Erbe, Yan Liu, Ailin Jin et autres

Background Despite advances in immune checkpoint inhibitor (ICI) biomarker molecular testing, there remains an unmet clinical need for more sensitive and generalizable biomarkers to better predict patient outcomes to ICI. This has been challenging due to the limited availability of multi-omic testing …

us (code pays fourni par la source)

PanIN and CAF transitions in pancreatic carcinogenesis revealed with spatial data integration

Alexander T.F. Bell, Jacob T. Mitchell, Ashley L. Kiemen, Melissa R. Lyman et autres

us (code pays fourni par la source)

Abstract 4027: From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC

Amanda Poissonnier, Eivind Valen Egeland, Wesley Horton, Shamilene Sivagnanam et autres

Abstract Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer, associated with limited treatment options and high mortality rates. Although immune checkpoint inhibitors (ICIs) show promise, early clinical results indicate benefits in only a specific subset of patients with TNBC. …

gb, us (code pays fourni par la source)